Your browser doesn't support javascript.
loading
A prognostic index predicting survival in transformed Waldenström macroglobulinemia.
Durot, Eric; Kanagaratnam, Lukshe; Zanwar, Saurabh; Kastritis, Efstathios; D'Sa, Shirley; Garcia-Sanz, Ramon; Tomowiak, Cécile; Hivert, Bénédicte; Toussaint, Elise; Protin, Caroline; Abeykoon, Jithma P; Guerrero-Garcia, Thomas; Itchaki, Gilad; Vos, Josephine M; Michallet, Anne-Sophie; Godet, Sophie; Dupuis, Jehan; Leprêtre, Stéphane; Bomsztyk, Joshua; Morel, Pierre; Leblond, Véronique; Treon, Steven P; Dimopoulos, Meletios A; Kapoor, Prashant; Delmer, Alain; Castillo, Jorge J.
Afiliación
  • Durot E; Department of Hematology, University Hospital of Reims and UFR Médecine, Reims. edurot@chu-reims.fr.
  • Kanagaratnam L; Department of Research and Innovation, University Hospital of Reims, Reims.
  • Zanwar S; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
  • Kastritis E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens.
  • D'Sa S; University College London Hospitals (UCLH) NHS Foundation Trust, London.
  • Garcia-Sanz R; Department of Hematology, University Hospital of Salamanca, CIBERONC and Research Biomedical Institute of Salamanca (IBSAL), Salamanca.
  • Tomowiak C; Department of Hematology and CIC U1402, University Hospital of Poitiers, Poitiers.
  • Hivert B; Department of Hematology, Hospital of Lens, Lens.
  • Toussaint E; Department of Hematology, University Hospital of Strasbourg, Strasbourg.
  • Protin C; Department of Hematology, IUCT Oncopole, Toulouse.
  • Abeykoon JP; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
  • Guerrero-Garcia T; Department of Hematology/Oncology, Delbert Day Cancer Institute, Rolla, MO.
  • Itchaki G; Institute of Hematology, Rabin Medical Center, Sackler Medical School, Tel-Aviv University, Israel.
  • Vos JM; Amsterdam University Medical Center (UMC) and LYMMCARE, Amsterdam.
  • Michallet AS; Department of Hematology, Léon Bérard Center, Lyon.
  • Godet S; Department of Hematology, University Hospital of Reims and UFR Médecine, Reims.
  • Dupuis J; Lymphoid Malignancies Unit, Henri Mondor Hospital, Créteil.
  • Leprêtre S; Inserm U1245 and Department of Hematology, Henri Becquerel Center and Normandie University UNIROUEN, Rouen.
  • Bomsztyk J; University College London Hospitals (UCLH) NHS Foundation Trust, London.
  • Morel P; Department of Hematology, University Hospital of Amiens, Amiens.
  • Leblond V; Department of Hematology, Pitié-Salpêtrière Hospital and Sorbonne University, UPMC Paris, GRECHY.
  • Treon SP; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens.
  • Kapoor P; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
  • Delmer A; Department of Hematology, University Hospital of Reims and UFR Médecine, Reims.
  • Castillo JJ; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Haematologica ; 106(11): 2940-2946, 2021 11 01.
Article en En | MEDLINE | ID: mdl-33179472
ABSTRACT
Histological transformation into diffuse large B-cell lymphoma is a rare complication in patients with Waldenström macroglobulinemia (WM) usually associated with a poor prognosis. The objective of this study was to develop and validate a prognostic index for survival in transformed WM patients. Through this multicenter, international collaborative effort, we developed a scoring system based on data from 133 patients with transformed WM who were evaluated between 1995 and 2016 (training cohort). Univariate and multivariate analyses were used to propose a prognostic index with 2-year survival after transformation as an end-point. For external validation, a data set of 67 patients was used to evaluate the performance of the model (validation cohort). By multivariate analysis, three adverse covariates were identified as independent predictors of 2-year survival after transformation elevated serum LDH (2 points), platelet count < 100 x 109/L (1 point) and any previous treatment for WM (1 point). Three risk groups were defined low-risk (0-1 point, 24% of patients), intermediate-risk (2-3 points, 59%, hazard ratio (HR) = 3.4) and high-risk (4 points, 17%, HR = 7.5). Two-year survival rates were 81%, 47%, and 21%, respectively (P < 0.0001). This model appeared to be a better discriminant than the International Prognostic Index (IPI) and the revised IPI (R-IPI). We validated this model in an independent cohort. This easy-to-compute scoring index is a robust tool that may allow identification of groups of transformed WM patients with different outcomes and could be used for improving the development of risk-adapted treatment strategies.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Macroglobulinemia de Waldenström Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Haematologica Año: 2021 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Macroglobulinemia de Waldenström Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Haematologica Año: 2021 Tipo del documento: Article